Form 4: 10x Genomics CFO Justin J. McAnear Reports Acquisition of Restricted Stock Units

Justin J. McAnear, CFO of 10x Genomics, reports the acquisition of restricted stock units (RSUs) representing a contingent right to receive Class A Common Stock.

Summary

• On March 21, 2024, Justin J. McAnear, the Chief Financial Officer of 10x Genomics, Inc. acquired 53,312 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were acquired at a price of $0.
• Following the transaction, McAnear directly owns 148,552 shares of Class A Common Stock.
• The RSUs vest in 1/16th increments quarterly, starting from February 21, 2024, contingent upon continued service as a provider.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units being granted, which is neither particularly positive nor negative.

Positives

• The acquisition of RSUs by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person continuing as a service provider.

Industry Context

This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency into the holdings of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive compensation and ownership.

Key Dates